Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
Alessandra IurloDaniele CattaneoAlessandra MalatoVincenzo AccursoMario AnnunziataAntonella GozziniAnna Rita ScortechiniCristina BucelliEmilia ScalzulliImma AttolicoAlessandro MaggiBruno MartinoGiovanni CaocciElisabetta AbruzzesePatrizia PregnoLuigiana LucianoMassimo BrecciaPublished in: American journal of hematology (2020)